New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareExenatide vs Tirzepatide

Exenatide vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsCognitive Enhancement
Exenatide
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
~5 days
Admin Route
SubQ
SubQ
Research
Typical Dose
5 mcg, titrate to 10 mcg
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Twice daily
Once weekly, subcutaneous
Key Benefits
  • Blood glucose control in type 2 diabetes
  • Weight loss (average 2–3 kg in clinical trials)
  • Once-weekly extended-release formulation available
  • Reduces appetite and food intake
  • Possible neuroprotective in Parkinson's disease (Phase II trials)
  • Reduces systemic inflammation
  • May protect pancreatic beta cells
  • Cardiovascular neutral or potentially protective
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Nausea (most common, especially initially)
  • Vomiting
  • Diarrhea
  • Headache
  • +4 more
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With